-
![Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors](/abs-image/US/2015/12/24/US20150366874A1/abs.jpg.150x150.jpg)
1.发明申请Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors 审中-公开新型4-（取代氨基）-7H-吡咯并[2,3-d]嘧啶作为LRRK2抑制剂公开(公告)号：US20150366874A1
公开(公告)日：2015-12-24
申请号：US14840528
申请日：2015-08-31
Applicant: Pfizer Inc.
Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Antonia Friederike Stepan , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest
IPC: A61K31/5377
CPC classification number: A61K31/5377 , C07D487/04 , C07D519/00
Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Abstract translation: 本发明提供了式I的新的4,5-二取代的-7H-吡咯并[2,3-d]嘧啶衍生物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如说明书中所定义。 本发明还涉及包含式I化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默病，神经变性疾病或克罗恩病或麻风病的神经变性疾病。
-
![Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors](/abs-image/US/2017/05/09/US09642855B2/abs.jpg.150x150.jpg)
公开(公告)号：US09642855B2
公开(公告)日：2017-05-09
申请号：US14840528
申请日：2015-08-31
Applicant: Pfizer Inc.
Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Antonia Friederike Stepan , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest
IPC: A61K31/519 , C07D487/04 , A61K31/5377 , C07D519/00
CPC classification number: A61K31/5377 , C07D487/04 , C07D519/00
Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
-
![NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS](/abs-image/US/2017/01/05/US20170002000A1/abs.jpg.150x150.jpg)
3.发明申请NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS 审中-公开新的3,4-取代的1H-吡咯并[2,3-b]吡啶和4,5-取代的-7H-吡咯并[2,3-c]吡咯烷作为LRRK2抑制剂公开(公告)号：US20170002000A1
公开(公告)日：2017-01-05
申请号：US15104659
申请日：2014-12-03
Applicant: PFIZER INC.
Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest , Antonia Friederike Stepan
IPC: C07D471/04 , C07D491/08 , C07D498/08 , C07D519/00 , C07D487/04
CPC classification number: C07D471/04 , C07D487/04 , C07D491/08 , C07D498/08 , C07D519/00
Abstract: The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Abstract translation: 其中R1，R2，R3，R4和X如说明书中所定义。 本发明还涉及包含式I化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默病，神经变性疾病或克罗恩病或麻风病的神经变性疾病。
-
![4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors](/abs-image/US/2015/10/13/US09156845B2/abs.jpg.150x150.jpg)
4.发明授权4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors 有权4-（取代氨基）-7H-吡咯并[2,3-d]嘧啶作为LRRK2抑制剂公开(公告)号：US09156845B2
公开(公告)日：2015-10-13
申请号：US13928696
申请日：2013-06-27
Applicant: Pfizer Inc.
Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Antonia Friederike Stepan , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest
IPC: A61K31/519 , C07D207/18 , C07D487/04 , C07D519/00
CPC classification number: A61K31/5377 , C07D487/04 , C07D519/00
Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Abstract translation: 本发明提供了式I的新的4,5-二取代的-7H-吡咯并[2,3-d]嘧啶衍生物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如说明书中所定义。 本发明还涉及包含式I化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默病，神经变性疾病或克罗恩病或麻风病的神经变性疾病。
-
![Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors](/abs-image/US/2022/04/26/US11312713B2/abs.jpg.150x150.jpg)
公开(公告)号：US11312713B2
公开(公告)日：2022-04-26
申请号：US16492558
申请日：2018-03-06
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Thomas Allen Chappie , Jinshan Michael Chen , Jotham Wadsworth Coe , Karen Jean Coffman , Paul Galatsis , Michelle Renee Garnsey , Christopher John Helal , Jaclyn Louise Henderson , Bethany Lyn Kormos , Ravi G. Kurumbail , Luis Angel Martinez-Alsina , Martin Youngjin Pettersson , Matthew Richard Reese , Colin Richard Rose , Antonia Friederike Stepan , Patrick Robert Verhoest , Travis T. Wager , Joseph Scott Warmus , Yuan Zhang
IPC: C07D471/04
Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
-
Patent Agency Ranking
![Cyclic substituted imidazo[4,5-c]quinoline derivatives](/abs-image/US/2021/11/02/US11161844B2/abs.jpg.150x150.jpg)
公开(公告)号：US11161844B2
公开(公告)日：2021-11-02
申请号：US16492554
申请日：2018-03-01
Applicant: Pfizer Inc.
Inventor： Thomas Allen Chappie , Paul Galatsis , Michelle Renee Garnsey , Christopher John Helal , Jaclyn Louise Henderson , Bethany Lyn Kormos , Ravi G. Kurumbail , Luis Angel Martinez-Alsina , Martin Youngjin Pettersson , Antonia Friederike Stepan , Travis T. Wager
IPC: C07D471/04 , C07D471/14
Abstract: The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
-
![CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES](/abs-image/US/2020/02/06/US20200039977A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200039977A1
公开(公告)日：2020-02-06
申请号：US16492554
申请日：2018-03-01
Applicant: Pfizer Inc.
Inventor： Thomas Allen Chappie , Paul Galatsis , Michelle Renee Garnsey , Christopher John Helal , Jaclyn Louise Henderson , Bethany Lyn Kormos , Ravi G. Kurumbail , Luis Angel Martinez-Alsina , Martin Youngjin Pettersson , Antonia Friederike Stepan , Travis T. Wager
IPC: C07D471/04 , C07D471/14
Abstract: The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
-
![Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors](/abs-image/US/2018/08/07/US10039753B2/abs.jpg.150x150.jpg)
8.发明授权公开(公告)号：US10039753B2
公开(公告)日：2018-08-07
申请号：US15262112
申请日：2016-09-12
Applicant: Pfizer Inc.
Inventor： Karen Jean Coffman , Paul Galatsis , Michelle Renee Garnsey , Jaclyn Louise Henderson , Bethany Lyn Kormos , Ravi G. Kurumbail , Martin Youngjin Pettersson , Matthew Richard Reese , Antonia Friederike Stepan , Patrick Robert Verhoest , Travis T. Wager
IPC: A61K31/435 , C07D215/38 , C07D471/04 , C07D519/00 , C07D471/14 , C07D215/42 , A61K31/4745
CPC classification number: A61K31/435 , A61K31/4745 , C07D215/38 , C07D215/42 , C07D471/04 , C07D471/14 , C07D519/00
Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
-
![3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors](/abs-image/US/2017/07/04/US09695171B2/abs.jpg.150x150.jpg)
公开(公告)号：US09695171B2
公开(公告)日：2017-07-04
申请号：US15104659
申请日：2014-12-03
Applicant: Pfizer Inc.
Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest , Antonia Friederike Stepan
IPC: C07D471/04 , C07D487/04 , C07D519/00 , C07D491/08 , C07D498/08
CPC classification number: C07D471/04 , C07D487/04 , C07D491/08 , C07D498/08 , C07D519/00
Abstract: The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
-
![Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors](/abs-image/US/2017/03/16/US20170073343A1/abs.jpg.150x150.jpg)
10.发明申请Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors 审中-公开新的咪唑并[4,5-c]喹啉和咪唑并[4,5-c] [1,5]萘啶衍生物作为LRRK2抑制剂公开(公告)号：US20170073343A1
公开(公告)日：2017-03-16
申请号：US15262112
申请日：2016-09-12
Applicant: Pfizer Inc.
Inventor： Paul Galatsis , Jaclyn Louise Henderson , Bethany Lyn Kormos , Ravi G. Kurumbail , Matthew Richard Reese , Antonia Friederike Stepan , Patrick Robert Verhoest , Travis T. Wager , Martin Youngjin Pettersson , Michelle Renee Garnsey
IPC: C07D471/04 , C07D471/14 , C07D519/00
CPC classification number: A61K31/435 , A61K31/4745 , C07D215/38 , C07D215/42 , C07D471/04 , C07D471/14 , C07D519/00
Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Abstract translation: 其中R1，R1a，R1b，R2，R4，R5，R6，X和Z如说明书中所定义。 本发明还涉及包含式（I）化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默氏病，癌症，克罗恩病或麻风病的神经变性疾病。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.033 seconds)
